AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8517510
Drug: High-dose adrenaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose adrenaline (10 mg every five minutes)
Trial: 8517510
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of adrenaline (1 mg every five minutes)
Trial: 3318052
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiethylperazine and antihistaminic (diphenhydramine)
Trial: 3318052
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiethylperazine and tricyclic antidepressant (amitriptyline)
Trial: 24719063
Drug: Topical liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical liposomal Rose Bengal (LRB) gel followed by intense pulsed light (IPL) treatment
Trial: 24719063
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel followed by intense pulsed light (IPL) treatment
Trial: 22388466
Drug: Ziprasidone (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (35 mg/d)
Trial: 12519461
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg haloxazolam (HAX)
Trial: 12519461
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg flunitrazepam (FNZ)
Trial: 12519461
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg triazolam (TRI)
Trial: 1847796
Drug: Intravenous cefoxitin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefoxitin, 1 g every 6 hours for 5 days
Trial: 18386570
Drug: Quxie Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quxie Capsule (QXC)
Trial: 2104084
Drug: Octreotide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (50 micrograms, single subcutaneous injection)
Trial: 31097088
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic vinorelbine (OMV) 50 mg three-times weekly
Trial: 30114980
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy
Trial: 19726290
Drug: Remifentanil preconditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil preconditioning (5 microg/kg in 50 ml normal saline)
Trial: 15771036
Drug: Usual postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual postoperative treatment with a pain control program
Trial: 9477007
Drug: Risperidone 16
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone 16 mg/day
Trial: 7537286
Drug: Haloperidol 20
RxNorm normalized name: haloperidol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 20 mg/day
Trial: 2737236
Drug: Diclofenac Na
RxNorm normalized name: DICLOFENAC NA 1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac Na 100 mg daily for 14 days
Trial: 1102233
Drug: Benzquinamide, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzquinamide, 100 mg 3 times daily
Trial: 1102233
Drug: Prochlorperazine, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochlorperazine, 10 mg 3 times daily
Trial: 28723831
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 7.5 mg
Trial: 28723831
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 10.0 mg
Trial: 28723831
Drug: Intrathecal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bupivacaine 7.5 mg or higher
Trial: 14562564
Drug: Prophylactic antifibrinolytic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antifibrinolytic therapy
Trial: 16897906
Drug: Live music
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live music therapy
Trial: 11581553
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE) at a dose of 3.5 mg/kg body weight administered by deep intramuscular injection once a week for 12 weeks
Trial: 3086177
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg)
Trial: 26259134
Drug: GH 1
RxNorm normalized name: Cough 100mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 1 mg/m(2) per day with GnRHa
Trial: 26259134
Drug: GH 2
RxNorm normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 2 mg/m(2) per day with GnRHa
Trial: 26259134
Drug: GH 1
RxNorm normalized name: Cough 100mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 1 mg/m(2) per day
Trial: 26259134
Drug: GH 2
RxNorm normalized name: ColdCough 2mg-7.5mg-15mg/5ml Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 2 mg/m(2) per day
Trial: 22071701
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (2 mg/kg daily)
Trial: 22071701
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (1 mg/kg daily)
Trial: 22071701
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg/kg daily)
Trial: 30699415
Drug: Enarodustat 2
RxNorm normalized name: Enarodustat
DrugBank: Enarodustat (DB14985)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Enarodustat 2 mg, 4 mg, or 6 mg once daily for 6 weeks (Period 1) followed by 24 weeks of open enarodustat treatment (Period 2)
Trial: 30699415
Drug: Enarodustat (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enarodustat (various doses)
Trial: 8441107
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline therapy
Trial: 3535158
Drug: Aspirin (high-dose)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (high-dose)
Trial: 14984383
Drug: Aspirin (low-dose)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (low-dose)
Trial: 3535158
Drug: Heparin-Dihydroergotamine (heparin-DHE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-Dihydroergotamine (heparin-DHE)
Trial: 18794104
Drug: Intravenous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous IL-2 (18 x 10(6) IU/m(2)/d) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Trial: 18794104
Drug: Subcutaneous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL-2 (9 x 10(6) or 18 x 10(6) IU) + s.c. IFN-alpha (6 x 10(6) IU 3 days/week)
Trial: 18794104
Drug: Intravenous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous IL-2
Trial: 18794104
Drug: Subcutaneous IL-2
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous IL-2
Trial: 12505245
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 mg/d)
Trial: 26704170
Drug: Other nonstandard
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other nonstandard therapies
Trial: 25182696
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to a biologic drug based on NICE guidelines
Trial: 25182696
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice for switching biologic drugs
Trial: 25182696
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of a biologic drug due to lack of effect
Trial: 1783248
Drug: Lactitol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactitol (20 g)
Trial: 1783248
Drug: Maltitol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltitol (20 g)
Trial: 1975490
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with morphine sulfate
Trial: 1542838
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) morphine sulfate
Trial: 7437259
Drug: Intravenous heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heroin (diamorphine) 2.5 mg and 5 mg for non-dependent; 1/6, 1/3, and 1/2 of prescribed daily dose for dependent subjects
Trial: 25934175
Drug: Interpersonal Community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal Community Psychiatric Treatment (ICPT)
Trial: 28800895
Drug: WeCareAdvisor™ (immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WeCareAdvisor™ (immediate treatment group)
Trial: 28800895
Drug: WeCareAdvisor™ (delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WeCareAdvisor™ (delayed treatment group)
Trial: 21235696
Drug: Pioglitazone 30
RxNorm normalized name: pioglitazone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg q.d. monotherapy
Trial: 19491283
Drug: Cetuximab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (400 mg/m² on week 1 followed by 250 mg/m² weekly)
Trial: 17218374
Drug: Controlled-release oxycodone
RxNorm normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Controlled-release oxycodone 15 mg
Trial: 16676098
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 100 mg/day for one month
Trial: 11182175
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg once daily
Trial: 7848024
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg once daily
Trial: 7740012
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of classroom and television delivery
Trial: 2405349
Drug: Aztreonam, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam, 150 mg/kg/day intravenously
Trial: 23485845
Drug: Thrust and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrust and nonthrust manipulation and exercise with myofascial therapy
Trial: 23485845
Drug: Thrust and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrust and nonthrust manipulation and exercise without myofascial therapy
Trial: 20806430
Drug: Probiotic group
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic group (sulfasalazine 2400 mg/d with probiotic)
Trial: 20806430
Drug: Sulfasalazine group
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine group (sulfasalazine 2400 mg/d)
Trial: 18821688
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 mg/kg from baseline through week 96, administered every 6 weeks after a loading dose
Trial: 18821688
Drug: Placebo through
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo through week 24 and then infliximab 5 mg/kg from week 24 through week 96
Trial: 18821688
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control cohort from OASIS database (no prior use of anti-TNF agents)
Trial: 12461760
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release melatonin 6 mg
Trial: 8554944
Drug: Selegiline (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (four doses of 10 mg over the preceding 3 days)
Trial: 1710660
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of gamma globulin (IVGG) plus aspirin
Trial: 31131679
Drug: Active SBCM
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active SBCM (treatment)
Trial: 17362495
Drug: Conventional two-stage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional two-stage restoration with tapered, roughened-surface Southern implants, provisional screw-retained crowns placed after 26 weeks, and definitive crowns placed 8 weeks later
Trial: 8348391
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg bid
Trial: 11895463
Drug: No intracoronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intracoronary treatment (group 1)
Trial: 17696673
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment conditions
Trial: 14621851
Drug: Monoclonal T‐cell‐specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal T‐cell‐specific antibodies (OKT3) for 7 days (n = 27)
Trial: 24199581
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride
Trial: 31574106
Drug: Control sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control sessions (conventional therapy)
Trial: 25348544
Drug: 1 implant
RxNorm normalized name: LEUPROLIDE ACETATE 72 MILLIGRAM In 1 IMPLANT SUBCUTANEOUS IMPLANT [Viadur]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 implant in the midline (group 1)
Trial: 25348544
Drug: 2 implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 implants in the canine areas (group 2)
Trial: 15172654
Drug: i.v. ibutilide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ibutilide treatment, up to 2 mg
Trial: 8737553
Drug: Caudal bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal bupivacaine (0.5ml/kg body weight of 0.25% solution)
Trial: 3297570
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of ampicillin (1 g X 3) and metronidazole (0.5 g X 3)
Trial: 3297570
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of metronidazole and ampicillin
Trial: 28589493
Drug: Omarigliptin 25
RxNorm normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Omarigliptin 25 mg once weekly
Trial: 9631989
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once weekly
Trial: 28923291
Drug: Prohibited medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prohibited medication (metformin)
Trial: 19593171
Drug: Flumazenil (FMZ)
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil (FMZ) 2 mg incremental bolus for 20 minutes for 2 consecutive days and Gabapentin (GBP) up to 1200 mg nightly for 39 days
Trial: 17203620
Drug: Antidepressants prescribed
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants prescribed at effective doses
Trial: 11125428
Drug: ISP- (isolated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISP- (isolated soy protein beverage providing 2.1 mg. of genistein and 1.3 mg. of daidzein daily)
Trial: 16649828
Drug: Atomoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (10 weeks treatment)
Trial: 16649828
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 weeks treatment)
Trial: 31850360
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group
Trial: 19723128
Drug: 1% voriconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% voriconazole eye drops, hourly for four doses
Trial: 1163927
Drug: New topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New topical ophthalmic delivery systems (specific systems not detailed)
Trial: 1163927
Drug: New topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New topical ophthalmic delivery systems
Trial: 26237623
Drug: PPIA preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPIA preparation
Trial: 22646659
Drug: Daily text
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily text message intervention (N = 8)
Trial: 22646659
Drug: Weekly general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly general health messages (N = 10)
Trial: 21069290
Drug: Intravenous sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sildenafil (low, medium, and high doses)
Trial: 20019427
Drug: Experimental bonding
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental bonding agents containing calcium phosphates
Trial: 16455838
Drug: Salbutamol pressurised
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol pressurised metered-dose inhaler 1,600 microg (metered)
Trial: 8842656
Drug: Intravenous nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalbuphine hydrochloride 0.3 mg kg‐1 (n = 21)
Trial: 7208540
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg clonidine sustained-release capsule, single oral dose, administered for 3 consecutive days
Trial: 18824662
Drug: Calcium plus
RxNorm normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium plus Vitamin D3 (1000 mg of elemental calcium plus 400 IU of vitamin D3 daily)
Trial: 16080281
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg tablets
Trial: 12457629
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg daily azithromycin
Trial: 12457629
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg daily azithromycin
Trial: 10370876
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet with red wine supplementation (240 ml/day)
Trial: 1466214
Drug: Scopolamine 0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.24 mg plus morphine 8 mg (Group 2)
Trial: 1466214
Drug: Atropine 0.5
RxNorm normalized name: homatropine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.5 mg plus pethidine 50 mg (Group 1)
Trial: 6700284
Drug: Short-term group
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term group therapy (15 weekly sessions)
Trial: 6700284
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list (no immediate treatment)
Trial: 23415202
Drug: Conventional antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antibiotic treatment
Trial: 21306419
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg scopolamine administered i.v.
Trial: 15070921
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (1 mg daily) with cyclic micronized progesterone (200 mg for 10 days/month)
Trial: 15070921
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol with cyclic micronized progesterone
Trial: 11286153
Drug: Statins (lipid-modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (lipid-modifying therapy)
Trial: 24440672
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg once daily)
Trial: 24440672
Drug: Mesalamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (3 g once daily)
Trial: 18375270
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine at 2 mL/hr
Trial: 18375270
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine at 5 mL/hr
Trial: 10921699
Drug: GIK (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (500 mL D5W + 80 U regular insulin + 40 mEq KCl at 30 mL/hour)
Trial: 10921699
Drug: No-GIK (D5W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-GIK (D5W at 30 mL/hour)
Trial: 1610422
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine
Trial: 3518290
Drug: Ambroxol 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol 1,000 mg in 500 ml 5% glucose infusion i.v. daily from day 1 to day 5 and 2 ml placebo‐injection i.m. on day 1 and day 2
Trial: 23094120
Drug: Praziquantel (PZQ)
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel (PZQ) treatment